• Nie Znaleziono Wyników

CHRONIC TREATMENT WITH CITALOPRAM DOES NOT AFFECT THE EXPRESSION OF a

N/A
N/A
Protected

Academic year: 2022

Share "CHRONIC TREATMENT WITH CITALOPRAM DOES NOT AFFECT THE EXPRESSION OF a"

Copied!
1
0
0

Pełen tekst

(1)

SHORT COMMUNICATION

CHRONIC TREATMENT WITH CITALOPRAM DOES NOT AFFECT THE EXPRESSION OF a

1

-ADRENERGIC RECEPTOR ( a

1

-AR) SUBTYPES

Grzegorz Kreiner, Adam Bielawski, Agnieszka Zelek-Molik, Marta Kowalska, Irena Nalepa



Laboratory of Intracellular Signaling, Department of Biochemistry, Institute of Pharmacology, Polish Academy of Sciences, Smêtna 12, PL 31-343 Kraków, Poland

Chronic treatment with citalopram does not affect the expression of a-adrenergic receptor subtypes. G. KREINER, A. BIELAWSKI, A. ZELEK- MOLIK, M. KOWALSKA, I. NALEPA. Pol. J. Pharmacol., 2004, 56, 831–836.

We previously reported that chronic treatment with imipramine and elec- troconvulsive shock up-regulate the density and a)-adrenergic receptor (a)-AR) mRNA level in the rat prefrontal cortex, while the expression of the a* subtype was unchanged. The present study examined whether re- peatedly given citalopram, a selective serotonin reuptake inhibitor, induces any changes in the expression ofa)anda*subtypes ofa-AR. The recep- tors density was assessed in the rat cerebral cortex by [!H]prazosin binding while the expression ofa)anda*receptors’ mRNA was measured in the rat prefrontal cortex by Northern blot analysis or competitive reverse tran- scription and polymerase chain reaction (RT-PCR), respectively. We did not find any changes ina)- anda*-AR density or mRNA expression in the in- vestigated rat brain structures of citalopram-treated rats. Thus, it seems that up-regulation ofa)-AR subtype is characteristic only of those antidepres- sant agents in which a noradrenergic component is involved in their pharma- cological mechanism of action.

Key words: citalopram, [!H]prazosin binding, mRNA expression, brain cortex, rat

Copyright © 2004 by Institute of Pharmacology

Polish Academy of Sciences Polish Journal of Pharmacology

Pol. J. Pharmacol., 2004, 56, 831–836 ISSN 1230-6002

 correspondence; e-mail: nfnalepa@cyf-kr.edu.pl

Cytaty

Powiązane dokumenty

Podsumowując, można stwierdzić, że ankietowani różnili się między sobą, jeśli chodzi o składowe otrzymywanego wspar- cia społecznego, ale nie różnili się w istotny sposób

and 4) finally for optimizing the primary result after stent implantation. Focusing on the rCART maneuver, there are four potential scenarios of antegrade and retrograde

Coronary angiography, fluoro- scopic digital stent enhancement (DSE), and intravascular ultrasound revealed recurrence of ISR in the proximal segment of the LAD caused by

Potent, transient in- hibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic

Na podstawie dotychczas opublikowanych wyników badań klinicznych można stwierdzić, że wenetoklaks stanowi skuteczną opcję leczenia chorych z nawrotową i oporną postacią CLL,

(początkowo i.v., następnie przy poprawie p.o.; dawkę zmniejszać gdy biegunka osłabnie do I stopnia według CTCAE; nie zaleca się ciągłe- go stosowania po ustąpieniu

Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically

Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib- -intolerant